Literature DB >> 17262005

Nonadherence to antipsychotic treatment in patients with schizophrenic disorders.

Jaromir Svestka1, Istvan Bitter.   

Abstract

Adherence to treatment is a general indicator of quality and success of communication between the physician and the patient. It means the extent to which patient behaviour, in terms of taking medications, following diets, or executing life-style changes, coincides with medical or health advice. Nonadherence to antipsychotic therapy in patients with schizophrenia is far more widespread than clinicians assume. Lower nonadherence in therapy based on antipsychotics of the second generation compared with conventional medications has already been indicated by early reports. The consequences of nonadherence include exacerbation of symptoms, an increased relapse rate, psychiatric hospitalization hospitalisation, and less favourable patient prognosis. There are several factors that cause treatment nonadherence in schizophrenia: causes derived from the schizophrenic disorder itself, patient characteristics, causes associated associated with the health-care system, and the antipsychotic treatment itself.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17262005

Source DB:  PubMed          Journal:  Neuro Endocrinol Lett        ISSN: 0172-780X            Impact factor:   0.765


  4 in total

1.  Does Non-Adherence Increase Treatment Costs in Schizophrenia?

Authors:  Mark Pennington; Paul McCrone
Journal:  Pharmacoeconomics       Date:  2018-08       Impact factor: 4.981

Review 2.  Telepsychiatry in the assessment and treatment of schizophrenia.

Authors:  John Kasckow; Kandi Felmet; Cathleen Appelt; Robert Thompson; Armando Rotondi; Gretchen Haas
Journal:  Clin Schizophr Relat Psychoses       Date:  2014-04

3.  Medication adherence in schizophrenia: factors influencing adherence and consequences of nonadherence, a systematic literature review.

Authors:  Kyoko Higashi; Goran Medic; Kavi J Littlewood; Teresa Diez; Ola Granström; Marc De Hert
Journal:  Ther Adv Psychopharmacol       Date:  2013-08

4.  Treatment Persistence Between Long-Acting Injectable Versus Orally Administered Aripiprazole Among Patients with Schizophrenia in a Real-World Clinical Setting in Japan.

Authors:  Nakao Iwata; Ataru Inagaki; Hiromi Sano; Kazunari Niidome; Yoshitsugu Kojima; Sakiko Yamada
Journal:  Adv Ther       Date:  2020-06-04       Impact factor: 3.845

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.